Additional file 1: Table S1. of Association between time of discharge from ICU and hospital mortality: a systematic review and meta-analysis

Database search strategies. Table S2. The justifications for the study exclusions (n = 26). Table S3. Newcastle-Ottawa quality assessment of included studies. Table S4. The main characteristics of the excluded meeting abstracts. (DOCX 98 kb

Additional file 2: of Association between time of discharge from ICU and hospital mortality: a systematic review and meta-analysis

PRISMA 2009 checklist. (DOC 62 kb

Additional file 3: Figure S1. of Association between time of discharge from ICU and hospital mortality: a systematic review and meta-analysis

Forest plots of the association between nighttime discharge from the ICU and hospital mortality stratified by geographic region. The size of each square is proportional to the study weight. Open diamonds represent the pooled OR. D + L refers to random effects and I-V to fixed effects. Figure S2. Forest plots of the association between nighttime discharge from the ICU and hospital mortality stratified by study design. The size of each square is proportional to the study weight. Open diamonds represent the pooled OR. D + L refers to random effects and I-V to fixed effects. Figure S3. Forest plots of the association between nighttime discharge from the ICU and hospital mortality stratified by the total discharge number. The size of each square is proportional to the study weight. Open diamonds represent the pooled OR. D + L refers to random effects and I-V to fixed effects. Figure S4. Funnel plots showing the association of nighttime discharge from the ICU with hospital mortality. s.e. refers to standard error, or refers to odds ratio. Figure S5. Funnel plots showing the association of weekend discharge from the ICU with hospital mortality. s.e. refers to standard error, or refers to odds ratio. (ZIP 395 kb

Enantioselective Bromolactonization of Deactivated Olefinic Acids

A novel enantioselective bromolactonization of α,β-unsaturated ketones using bifunctional amino-urea catalysts has been developed. The scope of the reaction is evidenced by 23 examples of halolactones bearing various functionalities with up to 99% yield and 99:1 er. Unlike typical urea catalysts that require electron-deficient substituents to enhance the hydrogen bond strength, it is interesting to realize that electron-rich ureas are essential for high enantioselectivity in this case. Moreover, experimental data reveals that the halolactone compounds exhibit considerable anti-inflammatory effects on LPS-induced RAW 264.7 cells

6‑Substituted Pyrrolo[2,3‑<i>d</i>]pyrimidine Thienoyl Regioisomers as Targeted Antifolates for Folate Receptor α and the Proton-Coupled Folate Transporter in Human Tumors

2-Amino-4-oxo-6-substituted-pyrrolo­[2,3-<i>d</i>]­pyrimidine antifolate thiophene regioisomers of AGF94 (<b>4</b>) with a thienoyl side chain and three-carbon bridge lengths [AGF150 (<b>5</b>) and AGF154 (<b>7</b>)] were synthesized as potential antitumor agents. These analogues inhibited proliferation of Chinese hamster ovary (CHO) sublines expressing folate receptors (FRs) α or β (IC₅₀s < 1 nM) or the proton-coupled folate transporter (PCFT) (IC₅₀ < 7 nM). Compounds <b>5</b> and <b>7</b> inhibited KB, IGROV1, and SKOV3 human tumor cells at subnanomolar concentrations, reflecting both FRα and PCFT uptake. AGF152 (<b>6</b>) and AGF163 (<b>8</b>), 2,4-diamino-5-substituted-furo­[2,3-<i>d</i>]­pyrimidine thiophene regioisomers, also inhibited growth of FR-expressing CHO and KB cells. All four analogues inhibited glycinamide ribonucleotide formyltransferase (GARFTase). Crystal structures of human GARFTase complexed with <b>5</b> and <b>7</b> were reported. In severe combined immunodeficient mice bearing SKOV3 tumors, <b>7</b> was efficacious. The selectivity of these compounds for PCFT and for FRα and β over the ubiquitously expressed reduced folate carrier is a paradigm for selective tumor targeting